{"id":1017555,"date":"2020-09-12T08:30:40","date_gmt":"2020-09-12T06:30:40","guid":{"rendered":"https:\/\/frezzapartners.com\/?p=1017555"},"modified":"2020-09-11T14:01:06","modified_gmt":"2020-09-11T12:01:06","slug":"partnership-bayer-recursion-malattie-fibrotiche-job-in-pharma","status":"publish","type":"post","link":"https:\/\/frezzapartners.com\/en\/partnership-bayer-recursion-malattie-fibrotiche-job-in-pharma\/","title":{"rendered":"Partnership Bayer-Recursion per rafforzare la piattaforma digitale di drug discovery e promuovere nuove terapie per le malattie fibrotiche"},"content":{"rendered":"<p>photo by <a href=\"https:\/\/www.bayer.com\/en\/\">Bayer<\/a><\/p>\n<p>&nbsp;<\/p>\n<p><span class=\"tlid-translation translation\" lang=\"it\">Bayer e Recursion Pharmaceuticals, Inc., societ\u00e0 biotech con sede negli Stati Uniti, <a href=\"https:\/\/media.bayer.com\/baynews\/baynews.nsf\/id\/Bayer-collaborates-Recursion-strengthen-digital-discovery-advance-therapies-fibrotic-diseases?Open&amp;parent=news-overview-category-search-en&amp;ccm=020\">hanno ufficialmente<\/a> stipulato un accordo di collaborazione strategica. La partnership sfrutter\u00e0 la piattaforma di drug discovery guidata dall&#8217;intelligenza artificiale costruita appositamente da Recursion e la libreria di composti di piccole molecole di Bayer e la profonda esperienza scientifica per scoprire e sviluppare nuovi trattamenti per le malattie fibrotiche del polmone, del rene, del cuore e altro ancora. E&#8217; <a href=\"https:\/\/leaps.bayer.com\/\">Leaps by Bayer<\/a>, la divisione Impact Investing di Bayer AG, che sta guidando il finanziamento di Recursion.<\/span><\/p>\n<p>&#8220;Stiamo portando avanti la trasformazione digitale nella ricerca e sviluppo poich\u00e9 crediamo che le tecnologie digitali come l&#8217;intelligenza artificiale e l&#8217;apprendimento automatico, offrano una miriade di nuove opportunit\u00e0 per affrontare la complessa biologia di molte malattie e identificare nuovi trattamenti per i pazienti&#8221;, ha affermato Joerg Moeller, MD , Membro del comitato esecutivo della divisione farmaceutica di Bayer AG e responsabile della ricerca e sviluppo. &#8220;La collaborazione con Recursion ci consente di scoprire farmaci candidati a piccole molecole mirati a una nuova biologia per il trattamento delle malattie fibrotiche e integra la nostra esperienza nella ricerca cardiovascolare con le tecnologie digitali&#8221;.<\/p>\n<p>Le malattie fibrotiche sono una causa significativa di morbilit\u00e0 e mortalit\u00e0 in tutto il mondo. Una delle maggiori sfide nel trattamento delle malattie fibrotiche \u00e8 la complessa biologia sottostante e la difficolt\u00e0 associata nello scoprire bersagli farmacologici rilevanti. Lo screening fenotipico \u00e8 un metodo per lo screening di nuove molecole terapeutiche per scoprire nuovi bersagli farmacologici e il loro ruolo nei processi patologici complessi. L&#8217;intelligenza artificiale e l&#8217;uso di metodi di apprendimento automatico consentono l&#8217;elaborazione di enormi quantit\u00e0 di dati &#8211; inclusa l&#8217;imaging ad alta risoluzione &#8211; generati da questi schermi e offre un potenziale senza precedenti per la scoperta di nuovi farmaci candidati per malattie con biologia complessa come le malattie fibrotiche.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>photo by Bayer &nbsp; Bayer e Recursion Pharmaceuticals, Inc., societ\u00e0 biotech con sede negli Stati Uniti, hanno ufficialmente stipulato un accordo di collaborazione strategica. La partnership sfrutter\u00e0 la piattaforma di drug discovery guidata dall&#8217;intelligenza artificiale costruita appositamente da Recursion e la libreria di composti di piccole molecole di Bayer e la profonda esperienza scientifica per scoprire e sviluppare nuovi trattamenti per le malattie fibrotiche del polmone, del rene, del cuore e altro ancora. E&#8217; Leaps by Bayer, la divisione Impact&#8230;<\/p>\n","protected":false},"author":297440,"featured_media":1017556,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[141],"tags":[2701,2887,2886,2665],"class_list":["post-1017555","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-bayer","tag-drug-discovery","tag-recursion","tag-usa"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Partnership Bayer-Recursion per rafforzare la piattaforma digitale di drug discovery e promuovere nuove terapie per le malattie fibrotiche - Frezza Partners<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/frezzapartners.com\/partnership-bayer-recursion-malattie-fibrotiche-job-in-pharma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Partnership Bayer-Recursion per rafforzare la piattaforma digitale di drug discovery e promuovere nuove terapie per le malattie fibrotiche - Frezza Partners\" \/>\n<meta property=\"og:description\" content=\"photo by Bayer &nbsp; Bayer e Recursion Pharmaceuticals, Inc., societ\u00e0 biotech con sede negli Stati Uniti, hanno ufficialmente stipulato un accordo di collaborazione strategica. La partnership sfrutter\u00e0 la piattaforma di drug discovery guidata dall&#8217;intelligenza artificiale costruita appositamente da Recursion e la libreria di composti di piccole molecole di Bayer e la profonda esperienza scientifica per scoprire e sviluppare nuovi trattamenti per le malattie fibrotiche del polmone, del rene, del cuore e altro ancora. E&#8217; Leaps by Bayer, la divisione Impact...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/frezzapartners.com\/partnership-bayer-recursion-malattie-fibrotiche-job-in-pharma\/\" \/>\n<meta property=\"og:site_name\" content=\"Frezza Partners\" \/>\n<meta property=\"article:published_time\" content=\"2020-09-12T06:30:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/09\/2019-7731-1024x683.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"683\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Frezza Partners\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Frezza Partners\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/partnership-bayer-recursion-malattie-fibrotiche-job-in-pharma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/partnership-bayer-recursion-malattie-fibrotiche-job-in-pharma\\\/\"},\"author\":{\"name\":\"Frezza Partners\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#\\\/schema\\\/person\\\/b953d1492c9f06a9923aed3b3cbe9fc0\"},\"headline\":\"Partnership Bayer-Recursion per rafforzare la piattaforma digitale di drug discovery e promuovere nuove terapie per le malattie fibrotiche\",\"datePublished\":\"2020-09-12T06:30:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/partnership-bayer-recursion-malattie-fibrotiche-job-in-pharma\\\/\"},\"wordCount\":327,\"image\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/partnership-bayer-recursion-malattie-fibrotiche-job-in-pharma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2020\\\/09\\\/2019-7731.jpg\",\"keywords\":[\"bayer\",\"drug discovery\",\"recursion\",\"usa\"],\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/partnership-bayer-recursion-malattie-fibrotiche-job-in-pharma\\\/\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/partnership-bayer-recursion-malattie-fibrotiche-job-in-pharma\\\/\",\"name\":\"Partnership Bayer-Recursion per rafforzare la piattaforma digitale di drug discovery e promuovere nuove terapie per le malattie fibrotiche - Frezza Partners\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/partnership-bayer-recursion-malattie-fibrotiche-job-in-pharma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/partnership-bayer-recursion-malattie-fibrotiche-job-in-pharma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2020\\\/09\\\/2019-7731.jpg\",\"datePublished\":\"2020-09-12T06:30:40+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#\\\/schema\\\/person\\\/b953d1492c9f06a9923aed3b3cbe9fc0\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/partnership-bayer-recursion-malattie-fibrotiche-job-in-pharma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/frezzapartners.com\\\/partnership-bayer-recursion-malattie-fibrotiche-job-in-pharma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/partnership-bayer-recursion-malattie-fibrotiche-job-in-pharma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2020\\\/09\\\/2019-7731.jpg\",\"contentUrl\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2020\\\/09\\\/2019-7731.jpg\",\"width\":2303,\"height\":1535,\"caption\":\"Bayer-Forscherin der Division Pharmaceuticals mit Zellkulturen ----------------------------- Bayer research scientist from the Pharmaceuticals Division in a Berlin laboratory\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/partnership-bayer-recursion-malattie-fibrotiche-job-in-pharma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/frezzapartners.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Partnership Bayer-Recursion per rafforzare la piattaforma digitale di drug discovery e promuovere nuove terapie per le malattie fibrotiche\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#website\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/\",\"name\":\"Frezza Partners\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/frezzapartners.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#\\\/schema\\\/person\\\/b953d1492c9f06a9923aed3b3cbe9fc0\",\"name\":\"Frezza Partners\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/en\\\/author\\\/fr3zz4partn3rs\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Partnership Bayer-Recursion per rafforzare la piattaforma digitale di drug discovery e promuovere nuove terapie per le malattie fibrotiche - Frezza Partners","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/frezzapartners.com\/partnership-bayer-recursion-malattie-fibrotiche-job-in-pharma\/","og_locale":"en_US","og_type":"article","og_title":"Partnership Bayer-Recursion per rafforzare la piattaforma digitale di drug discovery e promuovere nuove terapie per le malattie fibrotiche - Frezza Partners","og_description":"photo by Bayer &nbsp; Bayer e Recursion Pharmaceuticals, Inc., societ\u00e0 biotech con sede negli Stati Uniti, hanno ufficialmente stipulato un accordo di collaborazione strategica. La partnership sfrutter\u00e0 la piattaforma di drug discovery guidata dall&#8217;intelligenza artificiale costruita appositamente da Recursion e la libreria di composti di piccole molecole di Bayer e la profonda esperienza scientifica per scoprire e sviluppare nuovi trattamenti per le malattie fibrotiche del polmone, del rene, del cuore e altro ancora. E&#8217; Leaps by Bayer, la divisione Impact...","og_url":"https:\/\/frezzapartners.com\/partnership-bayer-recursion-malattie-fibrotiche-job-in-pharma\/","og_site_name":"Frezza Partners","article_published_time":"2020-09-12T06:30:40+00:00","og_image":[{"width":1024,"height":683,"url":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/09\/2019-7731-1024x683.jpg","type":"image\/jpeg"}],"author":"Frezza Partners","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Frezza Partners","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/frezzapartners.com\/partnership-bayer-recursion-malattie-fibrotiche-job-in-pharma\/#article","isPartOf":{"@id":"https:\/\/frezzapartners.com\/partnership-bayer-recursion-malattie-fibrotiche-job-in-pharma\/"},"author":{"name":"Frezza Partners","@id":"https:\/\/frezzapartners.com\/#\/schema\/person\/b953d1492c9f06a9923aed3b3cbe9fc0"},"headline":"Partnership Bayer-Recursion per rafforzare la piattaforma digitale di drug discovery e promuovere nuove terapie per le malattie fibrotiche","datePublished":"2020-09-12T06:30:40+00:00","mainEntityOfPage":{"@id":"https:\/\/frezzapartners.com\/partnership-bayer-recursion-malattie-fibrotiche-job-in-pharma\/"},"wordCount":327,"image":{"@id":"https:\/\/frezzapartners.com\/partnership-bayer-recursion-malattie-fibrotiche-job-in-pharma\/#primaryimage"},"thumbnailUrl":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/09\/2019-7731.jpg","keywords":["bayer","drug discovery","recursion","usa"],"articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/frezzapartners.com\/partnership-bayer-recursion-malattie-fibrotiche-job-in-pharma\/","url":"https:\/\/frezzapartners.com\/partnership-bayer-recursion-malattie-fibrotiche-job-in-pharma\/","name":"Partnership Bayer-Recursion per rafforzare la piattaforma digitale di drug discovery e promuovere nuove terapie per le malattie fibrotiche - Frezza Partners","isPartOf":{"@id":"https:\/\/frezzapartners.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/frezzapartners.com\/partnership-bayer-recursion-malattie-fibrotiche-job-in-pharma\/#primaryimage"},"image":{"@id":"https:\/\/frezzapartners.com\/partnership-bayer-recursion-malattie-fibrotiche-job-in-pharma\/#primaryimage"},"thumbnailUrl":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/09\/2019-7731.jpg","datePublished":"2020-09-12T06:30:40+00:00","author":{"@id":"https:\/\/frezzapartners.com\/#\/schema\/person\/b953d1492c9f06a9923aed3b3cbe9fc0"},"breadcrumb":{"@id":"https:\/\/frezzapartners.com\/partnership-bayer-recursion-malattie-fibrotiche-job-in-pharma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/frezzapartners.com\/partnership-bayer-recursion-malattie-fibrotiche-job-in-pharma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/frezzapartners.com\/partnership-bayer-recursion-malattie-fibrotiche-job-in-pharma\/#primaryimage","url":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/09\/2019-7731.jpg","contentUrl":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/09\/2019-7731.jpg","width":2303,"height":1535,"caption":"Bayer-Forscherin der Division Pharmaceuticals mit Zellkulturen ----------------------------- Bayer research scientist from the Pharmaceuticals Division in a Berlin laboratory"},{"@type":"BreadcrumbList","@id":"https:\/\/frezzapartners.com\/partnership-bayer-recursion-malattie-fibrotiche-job-in-pharma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/frezzapartners.com\/"},{"@type":"ListItem","position":2,"name":"Partnership Bayer-Recursion per rafforzare la piattaforma digitale di drug discovery e promuovere nuove terapie per le malattie fibrotiche"}]},{"@type":"WebSite","@id":"https:\/\/frezzapartners.com\/#website","url":"https:\/\/frezzapartners.com\/","name":"Frezza Partners","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/frezzapartners.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/frezzapartners.com\/#\/schema\/person\/b953d1492c9f06a9923aed3b3cbe9fc0","name":"Frezza Partners","url":"https:\/\/frezzapartners.com\/en\/author\/fr3zz4partn3rs\/"}]}},"_links":{"self":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/posts\/1017555","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/users\/297440"}],"replies":[{"embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/comments?post=1017555"}],"version-history":[{"count":0,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/posts\/1017555\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/media\/1017556"}],"wp:attachment":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/media?parent=1017555"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/categories?post=1017555"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/tags?post=1017555"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}